The use of inhaled corticosteroids in pediatric asthma: Update

World Allergy Organization Journal

Volumn 9, Issue 1, 2016, Pages

  Hossny, Elham ^a   Rosario, Nelson ^b   Lee, Bee Wah ^c,d   Singh, Meenu ^e   El Ghoneimy, Dalia ^a   Soh, Jian Yi ^c,d   Le Souef, Peter ^f  

^a Ain Shams University   (Egypt)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Adherence; Adverse effects; Asthma; Children; Inhaled corticosteroids

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; HEAT SHOCK PROTEIN 90; HEMOGLOBIN A1C; HISTONE ACETYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL TRISPHOSPHATE; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOCORTIN 1; LONG ACTING DRUG; MITOGEN ACTIVATED PROTEIN KINASE P38; MOMETASONE FUROATE; PREDNISONE; PROTEIN KINASE C; TRANSCRIPTION FACTOR AP 1; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ACNE; ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BONE DENSITY; BRONCHOSPASM; CATARACT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COUGHING; DENTAL CARIES; DIABETES MELLITUS; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; DYSPHONIA; ESOPHAGUS CANDIDIASIS; EVIDENCE BASED MEDICINE; FRACTURE; GLAUCOMA; GROWTH DISORDER; HAIR DISEASE; HUMAN; HYPOPHYSIS DISEASE; IMMUNITY; INHALATION SPACER; INTRAOCULAR HYPERTENSION; MEDICATION COMPLIANCE; METERED DOSE INHALER; NEBULIZER; NONHUMAN; ONSET AGE; OROPHARYNX CANDIDIASIS; OSTEOPOROSIS; PATIENT MONITORING; PHARYNGITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; QUALITY OF LIFE; REVIEW; RISK FACTOR; SKIN BRUISING; SKIN DISEASE; TASTE DISORDER; TREATMENT INDICATION; TREATMENT PLANNING; XEROSTOMIA;

EID: 84981523378     PISSN: None     EISSN: 19394551     Source Type: Journal    
DOI: 10.1186/s40413-016-0117-0     Document Type: Review

References (241)

1. Thomas M. Why aren't we doing better in asthma: time for personalised medicine? NPJ Prim Care Respir Med. 2015;25:15004.
2. Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gern J, Lemanske R, Le Souef P, Mäkelä M, Roberts G, Wong G, Zar H, Akdis CA, Bacharier LB, Baraldi E, van Bever HP, de Blic J, Boner A, Burks W, Casale TB, Castro-Rodriguez JA, Chen YZ, El-Gamal YM, Everard ML, Frischer T, Geller M, Gereda J, Goh DY, Guilbert TW, Hedlin G, Heymann PW, Hong SJ, Hossny EM, Huang JL, Jackson DJ, de Jongste JC, Kalayci O, Aït-Khaled N, Kling S, Kuna P, Lau S, Ledford DK, Lee SI, Liu AH, Lockey RF, Lødrup-Carlsen K, Lötvall J, Morikawa A, Nieto A, Paramesh H, Pawankar R, Pohunek P, Pongracic J, Price D, Robertson C, Rosario N, Rossenwasser LJ, Sly PD, Stein R, Stick S, Szefler S, Taussig LM, Valovirta E, Vichyanond P, Wallace D, Weinberg E, Wennergren G, Wildhaber J, Zeiger RS. International consensus on (ICON) pediatric asthma. Allergy. 2012;67:976-97.
3. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Updated April 2015. Available at: http://ginasthma.org/wp-content/uploads/2016/01/GINA-Pocket-2015.pdf. Accessed 30 January, 2016.
4. de Benedictis FM, Bush A. Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med. 2012;185:12-23.
5. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappa B or activator protein-1: molecular mechanisms for gene repression. Endocr Rev. 2003;24:488-522.
6. Adcock IM, Ito K, Barnes PJ. Glucocorticoid: effects on gene transcription. Proc Am Thorac Soc. 2004;1:247-54.
7. Chanez P, Bourdin A, Vachier I, Godard P, Bousquet J, Vignola AM. Effects of inhaled corticosteroids on pathology in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1:184-90.
8. Schwiebert LM, Stellato C, Schleimer RP. The epithelium as a target of glucocorticoid action in the treatment of asthma. Am J Respir Crit Care Med. 1996;154:S16-9.
9. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med. 2003;139(5):359-70.
10. Barnes PJ. Therapeutic strategies for allergic diseases. Nature. 1999;402:B 31-8.
11. Horvath G, Wanner A. Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur Respir J. 2006;27:172-87.
12. Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. Eur J Pharmacol. 2004;500:51-62.
13. Bannister AJ, Schneider R, Kouzarides T. Histone methylation: dynamic or static? Cell. 2002;109:801-6.
14. Barnes PJ. Inhaled corticosteroids. Pharmaceuticals. 2010;3:514-40.
15. Barnes PJ. How corticosteroids control inflammation. Br J Pharmacol. 2006;148:245-54.
16. Imhof A, Wolffe AP. Transcription: gene control by targeted histone acetylation. Curr Biol. 1998;8:R422-4.
17. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol. 2000;20:6891-903.
18. Reichardt HM, Tuckermann JP, Gottlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schütz G. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 2001;20:7168-73.
19. Hall SE, Lim S, Witherden IR, Tetley TD, Barnes PJ, Kamal AM, Smith SF. Lung type II cell and macrophage annexin I release: differential effects of two glucocorticoids. Am J Physiol. 1999;276:L114-21.
20. Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A. 2004;101:227-32.
21. Lasa M, Brook M, Saklatvala J, Clark AR. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol. 2001;21:771-80.
22. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol. 2002;22:7802-11.
23. Bartholome B, Spies CM, Gaber T, Schuchmann S, Berki T, Kunkel D, Bienert M, Radbruch A, Burmester GR, Lauster R, Scheffold A, Buttgereit F. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB J. 2004;18:70-80.
24. Horvath G, Wanner A. Molecular targets for steroids in airway vascular smooth muscle. Arch Physiol Biochem. 2003;111:341-4.
25. Borski RJ. Nongenomic membrane actions of glucocorticoids in vertebrates. Trends Endocrinol Metab. 2000;11:427-36.
26. Horvath G, Lieb T, Conner GE, Salathe M, Wanner A. Steroid sensitivity of norepinephrine uptake by human bronchial arterial and rabbit aortic smooth muscle cells. Am J Respir Cell Mol Biol. 2001;25:500-6.
27. Kumar SD, Brieva JL, Danta I, Wanner A. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am J Respir Crit Care Med. 2000;161:918-21.
28. Mendes ES, Pereira A, Danta I, Duncan RC, Wanner A. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J. 2003;21:989-93.
29. Schoonbrood DFM, Out TA, Lutter R, Reimert CM, Vanoverveld FJ, Jansen HM. Plasma-protein leakage and local secretion of proteins assessed in sputum in asthma and COPD - the effect of inhaled corticosteroids. Clin Chim Acta. 1995;240:163-78.
30. Kanazawa H, Hirata K, Yoshikawa J. Involvement of vascular endothelial growth factor in exercise induced bronchoconstriction in asthmatic patients. Thorax. 2002;57:885-8.
31. Nocker RE, Weller FR, Out TA, de Riemer MJ, Jansen HM, van der Zee JS. A double-blind study on the effect of inhaled corticosteroids on plasma protein exudation in asthma. Am J Respir Crit Care Med. 1999;159:1499-505.
32. Vandegraaf EA, Out TA, Roos CM, Jansen HM. Respiratory membrane-permeability and bronchial hyperreactivity in patients with stable asthma - effects of therapy with inhaled steroids. Am Rev Respir Dis. 1991;143:362-8.
33. Hoshino M, Takahashi M, Takai Y, Sim J, Aoike N. Inhaled corticosteroids decrease vascularity of the bronchial mucosa in patients with asthma. Clin Exp Allergy. 2001;31:722-30.
34. Chetta A, Zanini A, Foresi A, Del Donno M, Castagnaro A, D'Ippolito R, Baraldo S, Testi R, Saetta M, Olivieri D. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med. 2003;167:751-7.
35. Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses and increased bronchial responsiveness to histamine. J Allergy Clin Immunol. 1987;79:734-40.
36. Dahl R, Johansson SA. Importance of duration of treatment with inhaled budesonide on the immediate and late bronchial reaction. Eur J Respir Dis. 1982;63:167-75.
37. Gotshall RW. Exercise-induced bronchoconstriction. Drugs. 2002;62:1725-39.
38. Barnes PJ. Effects of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis. 1990;141:S70-6.
39. Adcock IM, Stevens DA, Barnes PJ. Interactions of glucocorticoids and β2-agonists. Eur Respir J. 1996;9:160-8.
40. Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, Block LH. Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem. 1999;274:1005-10.
41. Korn SH, Wouters EF, Wesseling G, Arends JW, Thunnissen FB. Interaction between glucocorticoids and β2-agonists: α- and β- glucocorticoid-receptor mRNA expression in human bronchial epithelial cells. Biochem Pharmacol. 1998;56:1561-9.
42. Usmani OS, Maneechotesuwan K, Adcock IM, Barnes PJ. Glucocorticoid receptor activation following inhaled fluticasone and salmeterol. Am J Respir Crit Care Med. 2005;15(172):704-12.
43. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002;99:8921-6.
44. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, Leichtl S, Rathgeb F, Keller A, Steinijans VW. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J. 1997;10:2754-60.
45. Lim S, Jatakanon A, Gordon D, Macdonald C, Chung KF, Barnes PJ. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax. 2000;55:837-41.
46. Szefler SJ, Leung DY. Glucocorticoid-resistant asthma: pathogenesis and clinical implications for management. Eur Respir J. 1997;10:1640-7.
47. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2003;111:3-22.
48. Spahn JD, Szefler SJ, Surs W, Doherty DE, Nimmagadda SR, Leung DY. A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity. J Immunol. 1996;157:2654-9.
49. Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tsai JJ, Frew AJ, Kay AB. Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis. 1991;144:1016-25.
50. Matthews JG, Ito K, Barnes PJ, Adcock IM. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol. 2004;113:1100-8.
51. Hamasaki Y, Kohno Y, Ebisawa M, Kondo N, Nishima S, Nishimuta T, Morikawa A, Aihara Y, Akasawa A, Adachi Y, Arakawa H, Ikebe T, Ichikawa K, Inoue T, Iwata T, Urisu A, Ohya Y, Okada K, Odajima H, Katsunuma T, Kameda M, Kurihara K, Sakamoto T, Shimojo N, Suehiro Y, Tokuyama K, Nambu M, Fujisawa T, Matsui T, Matsubara T, Mayumi M, Mochizuki H, Yamaguchi K, Yoshihara S. Japanese pediatric guideline for the treatment and management of bronchial asthma 2012. Pediatr Int. 2014;56:441-50.
52. Canadian Thoracic Society Asthma Committee. Diagnosis and management of asthma in preschoolers. 2015. Available from: http://www.respiratoryguidelines.ca/guideline/asthma.
53. Canadian Thoracic Society Asthma Committee. Diagnosis and management of asthma in preschoolers, children and adults. 2012. Available from: http://www.respiratoryguidelines.ca/guideline/asthma.
54. British Guideline on the Management of Asthma: a national clinical guideline. British Thoracic Society and Scottish Intercollegiate Guidelines Network. 2014. Available from: http://sign.ac.uk/guidelines/fulltext/141/index.html.
55. National Asthma Council Australia, Melbourne. Australian Asthma Handbook. 2015. Available from: http://www.asthmahandbook.org.au/download-order/complete-handbook.
56. Al-Moamary MS, Alhaider SA, Al-Hajjaj MS, Al-Ghobain MO, Idrees MM, Zeitouni MO, Al-Harbi AS, Al Dabbagh MM, Al-Matar H, Alorainy HS. The Saudi initiative for asthma - 2012 update: Guidelines for the diagnosis and management of asthma in adults and children. Ann Thorac Med. 2012;7:175-204.
57. South African Childhood Asthma Working group. Guideline for the management of chronic asthma in children. 2009. Available from: http://www.pulmonology.co.za/downloads/guidelines/Guideline-13.pdf.
58. Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Gotz M, Helms PJ, Hunt J, Liu A, Papadopoulos N, Platts-Mills T, Pohunek P, Simons FE, Valovirta E, Wahn U, Wildhaber J, Group EPA. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008;63:5-34.
59. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2007. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Available from: http://www.nhlbi.nih.gov/files/docs/guidelines/asthsumm.pdf.
60. Indian Academy of Pediatrics. Consensus statement on the diagnosis and asthma in children. 2001. Available from: http://isaac.auckland.ac.nz/resources/Asthma-3%20-guidelines.pdf.
61. Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev. 2013;2, CD009611.
62. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske Jr RF, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:650-7.
63. Amirav I, Newhouse MT. Deposition of small particles in the developing lung. Paediatr Respir Rev. 2012;13:73-8.
64. van Aalderen WM, Grigg J, Guilbert TW, Roche N, Israel E, Martin RJ, Colice G, Postma DS, Hillyer EV, Burden A, Thomas V, von Ziegenweidt J, Price D. Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma. J Allergy Clin Immunol Pract. 2015;3:721-31.
65. Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database System Rev. 2009;(4):CD005307.
66. Sorkness CA, Lemanske Jr RF, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Bloomberg GR, Covar RA, Guilbert TW, Heldt G, Larsen G, Mellon MH, Morgan WJ, Moss MH, Spahn JD, Taussig LM, Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2007;119:64-72.
67. Szefler SJ, Baker JW, Uryniak T, Goldman M, Silkoff PE. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol. 2007;120:1043-50.
68. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics. 2005;116:360-9.
69. Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, Crim C. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr. 2005;147:213-20.
70. Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol. 2006;117(1):45-52.
71. Wu AC, Li L, Fung V, Kharbanda EO, Larkin EK, Vollmer WM, Butler MG, Miroshnik I, Rusinak D, Davis RL, Hartert T, Weiss ST, Lieu TA. Use of leukotriene receptor antagonists are associated with a similar risk of asthma exacerbations as inhaled corticosteroids. J Allergy Clin Immunol Pract. 2014;2:607-13.
72. Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;12, CD009019.
73. Bisgaard H, Le Roux P, Bjåmer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest. 2006;130:1733-43.
74. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129-36.
75. Ni Chroinin M, Lasserson TJ, Greenstone I, Ducharme FM. Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev. 2009;3:CD007949.
76. Vaessen-Verberne AA, van den Berg NJ, van Nierop JC, Brackel HJ, Gerrits GP, Hop WC, Duiverman EJ, COMBO Study Group. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med. 2010;182:1221-7.
77. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012;5:CD002314.
78. Lemanske Jr RF, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Covar RA, Guilbert TW, Larsen G, Morgan WJ, Moss MH, Spahn JD, Taussig LM, Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010;362:975-85.
79. Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev. 2014;1:CD003137.
80. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest. 2000;117:440-6.
81. Oborne J, Mortimer K, Hubbard RB, Tattersfield AE, Harrison TW. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: A randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med. 2009;180:598-602.
82. Quon BS, Fitzgerald JM, Lemière C, Shahidi N, Ducharme FM. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;12, CD007524.
83. Garrett J, Williams S, Wong C, Holdaway D. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Arch Dis Child. 1998;79:12-7.
84. Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Arch Dis Child. 1990;65:407-10.
85. Svedmyr J, Nyberg E, Thunqvist P, Asbrink-Nilsson E, Hedlin G. Prophylactic intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. Acta Paediatr. 1999;88:42-7.
86. Yousef E, Hossain J, Mannan S, Skorpinski E, McGeady S. Early intervention with high-dose inhaled corticosteroids for control of acute asthma exacerbations at home and improved outcomes: a randomized controlled trial. Allergy Asthma Proc. 2012;33(6):508-13.
87. Chong J, Haran C, Chauhan BF, Asher I. Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults. Cochrane Database Syst Rev. 2015;7, CD011032.
88. Edmonds ML, Milan SJ, Camargo Jr CA, Pollack CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2012;12, CD002308.
89. Beckhaus AA, Riutort MC, Castro-Rodriguez JA. Inhaled versus systemic corticosteroids for acute asthma in children. A systematic review. Pediatr Pulmonol. 2014;49:326-34.
90. Su XM, Yu N, Kong LF, Kang J. Effectiveness of inhaled corticosteroids in the treatment of acute asthma in children in the emergency department: a meta-analysis. Ann Med. 2014;46:24-30.
91. Amirav I, Newhouse MT, Minocchieri S, Castro-Rodriguez JA, Schüepp KG. Factors that affect the efficacy of inhaled corticosteroids for infants and young children. J Allergy Clin Immunol. 2010;125:1206-11.
92. Everard M, Clark AR, Milner AD. Drug delivery from jet nebulisers. Arch Dis Child. 1992;67:586-91.
93. Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ. 2001;323:896-900.
94. Cates CJ, Adams N, Bestall J. Holding chambers versus nebulisers for inhaled steroids in chronic asthma. Cochrane Database Syst Rev. 2001;2, CD001491.
95. Grzelewska-Rzymowska I, Kroczynska-Bednarek J, Zarkovic J. Comparison of the efficacy and safety of high doses of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in steroid-dependent adults with moderate to severe asthma. Respir Med. 2003;97(Suppl B):S21-6.
96. Bisgaard H, Nikander K, Munch E. Comparative study of budesonide as a nebulized suspension vs pressurized metered-dose inhaler in adult asthmatics. Respir Med. 1998;92:44-9.
97. Dempsey OJ, Humphreys M, Coutie WJ, Lipworth BJ. Relative lung delivery of fluticasone propionate via large volume spacer or nebuliser in healthy volunteers. Eur J Clin Pharmacol. 2001;57:637-41.
98. Bisgaard H, Andersen JB, Bach-Mortensen N, Bertelsen A, Friis B, Koch C, Prahl P, Wichmann R, Osterballe O. A clinical comparison of aerosol and powder administration of beclomethasone dipropionate in childhood asthma. Allergy. 1984;39:365-9.
99. Adler LM, Anand C, Wright F, Barrett CF, McKeith D, Clark W, Maksimczyk P, Martin G, McKinnon C, Raffles A, Buck H. Efficacy and tolerability of beclomethasone dipropionate delivered by a novel multidose dry powder inhaler (Clickhaler®) versus a metered-dose inhaler in children with asthma. Curr Ther Res. 2001;62:758-69. Available from: http://www.sciencedirect.com/science/article/pii/S0011393X01800825.
100. Agertoft L, Pedersen S, Nikander K. Drug delivery from the Turbuhaler and Nebuhaler pressurized metered dose inhaler to various age groups of children with asthma. J Aerosol Med. 1999;12:161-9.
101. Backman R, Baumgarten C, Sharma RK. Fluticasone propionate via Diskus™ inhaler at half the microgram dose of budesonide via Turbuhaler™ inhaler. Clinical Drug Investigation. 2001;21:735-43. Available from: http://www.medscape.com/viewarticle/418159.
102. Amirav I, Mansour Y, Tiosano T, Chamny S, Chirurg S, Oren S, Grossman Z, Kahana L, Kahan E, Newhouse MT, Network I. Safety of inhaled corticosteroids delivered by plastic and metal spacers. Arch Dis Child. 2003;88:527-8.
103. Amirav I, Tiosano T, Chamny S, Chirurg S, Oren S, Grossman Z, Kahan E, Newhouse MT, Mansour Y, Network IPROS. Comparison of efficiency and preference of metal and plastic spacers in preschool children. Ann Allergy Asthma Immunol. 2004;93:249-52.
104. Brand PL, van der Baan-Slootweg OH, Heynens JW, de Vries TW, Versteegh FG, Vreuls RC, den Ouden WJ, Smit FJ. Comparison of handling and acceptability of two spacer devices in young children with asthma. Acta Paediatr. 2001;90:133-6.
105. Ammari WG, Toor S, Chetcuti P, Stephenson J, Chrystyn H. Evaluation of asthma control, parents' quality of life and preference between Aero Chamber Plus and AeroChamber Plus Flow-Vu spacers in young children with asthma. J Asthma. 2015;52:301-7.
106. Dhar R, Salvi S, Rajan S, Dalal S, Tikkiwal S, Bhagat R, Ahmed MM, Balki A, Jain M, Gogtay J. Salmeterol/fluticasone through breath-actuated inhaler versus pMDI: A randomized, double-blind, 12 weeks study. J Asthma. 2015;52:1065-72.
107. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med. 2006;100:1307-17.
108. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy. 2006;61:518-26.
109. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126:213-9.
110. Pinto CR, Almeida NR, Marques TS, Yamamura LL, Costa LA, Souza-Machado A. Local adverse effects associated with the use of inhaled corticosteroids in patients with moderate or severe asthma. J Bras Pneumol. 2013;39:409-17.
111. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med. 1995;332:868-75.
112. Godara N, Godara R, Khullar M. Impact of inhalation therapy on oral health. Lung India. 2011;28:272-5.
113. Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol. 2007;98:225-38.
114. Pingeleton WW, Bone RC, Kerby GR, Ruth WE. Oropharyngeal candidiasis in patients treated with triamcinolone acetonide aerosol. J Allergy Clin Immunol. 1977;60:254-8.
115. van Boven JF, de Jong-van den Berg LT, Vegter S. Inhaled corticosteroids and the occurrence of oral candidiasis: a prescription sequence symmetry analysis. Drug Saf. 2013;36:231-6.
116. Glavey SV, Keane N, Power M, O'Regan AW. Posterior pharyngeal candidiasis in the absence of clinically overt oral involvement: a cross-sectional study. Lung. 2013;191:663-8.
117. Fukushima C, Matsuse H, Tomari S, Obase Y, Miyazaki Y, Shimoda T, Kohno S. Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann Allergy Asthma Immunol. 2003;90:646-51.
118. Aun MV, Ribeiro MR, Costa Garcia CL, Agondi RC, Kalil J, Giavina-Bianchi P. Esophageal candidiasis - an adverse effect of inhaled corticosteroids therapy. J Asthma. 2009;46:399-401.
119. Hasosah MY, Showail M, Al-Sahafi A, Satti M, Jacobson K. Esophageal candidiasis in an immunocompetent girl. World J Pediatr. 2009;5:152-4.
120. Kanda N, Yasuba H, Takahashi T, Mizuhara Y, Yamazaki S, Imada Y, Izumi Y, Kobayashi Y, Yamashita K, Kita H, Tamada T, Chiba T. Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate. Am J Gastroenterol. 2003;98:2146-8.
121. Mullaoglu S, Turktas H, Kokturk N, Tuncer C, Kalkanci A, Kustimur S. Esophageal candidiasis and Candida colonization in asthma patients on inhaled steroids. Allergy Asthma Proc. 2007;28:544-9.
122. Galván CA, Guarderas JC. Practical considerations for dysphonia caused by inhaled corticosteroids. Mayo Clin Proc. 2012;87:901-4.
123. Chmielewska M, Akst LM. Dysphonia associated with the use of inhaled corticosteroids. Curr Opin Otolaryngol Head Neck Surg. 2015;23:255-9.
124. Gallivan GJ, Gallivan KH, Gallivan HK. Inhaled corticosteroids: hazardous effects on voice-an update. J Voice. 2007;21:101-11.
125. Wogelius P, Poulsen S, Sorensen HT. Use of asthma drugs and risk of dental caries among 5 to 7 year old Danish children: A cohort study. Community Dent Health. 2004;21:207-11.
126. Milano M, Lee JY, Donovan K, Chen JW. A crosssectional study of medication related factors and caries experience in asthmatic children. Pediatr Dent. 2006;28:415-9.
127. Porter SR, Scully C. Oral malodour (halitosis). BMJ. 2006;333:632-5.
128. McDerra EJ, Bjerkeborn K, Dahllof G, Hedlin G, Lindell M, Modeer T. Effect of disease severity and pharmacotherapy of asthma on oral health in asthmatic children. Scand J Dent Res. 1988;22:297-301.
129. Yokoyama H, Yamamura Y, Ozeki T, Iga T, Yamada Y. Influence of mouth washing procedures on the removal of drug residues following inhalation of corticosteroids. Biol Pharm Bull. 2006;29:1923-5.
130. Philip J. The effects of inhaled corticosteroids on growth in children. Open Respir Med J. 2014;8:66-73.
131. Allen DB. Inhaled corticosteroid therapy for asthma in preschool children: growth issues. Pediatrics. 2002;109(2 Suppl):373-80.
132. van Bever HP, Desager KN, Lijssens N, Weyler JJ, Du Caju MVL. Does treatment of asthmatic children with inhaled corticosteroids affect their adult height? Pediatr Pulmonol. 1999;27:369-75.
133. Inoue T, Doi S, Takamatsu I, Murayama N, Kameda M, Toyoshima K. Effect of long-term treatment with inhaled beclomethasone dipropionate on growth of asthmatic children. J Asthma. 1999;36:159-64.
134. Skoner DP, Szefler SJ, Welch M, Walton-Bowen K, Cruz-Rivera M, Smith JA. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. J Allergy Clin Immunol. 2000;105:259-68.
135. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. New Engl J Med. 2000;343:1064-9.
136. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, Ullman A, Lamm CJ, O'Byrne PM, Investigators Group START. Early intervention with budesonide in mild persistent asthma: a randomized, double-blind trial. Lancet. 2003;361:1071-6.
137. Stefanovic IM, Verona E, Cicak B, Vrsalovic R. No effect of fluticasone propionate on linear growth in preschool children with asthma. Pediatr Int. 2011;53:672-6.
138. Bensch GW, Greos LS, Gawchik S, Kpamegan E, Newman. Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2011;107:323-9.
139. Skoner DP, Meltzer EO, Milgrom H, Stryszak P, Teper A, Staudinger H. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma. J Asthma. 2011;48:848-59.
140. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, Raissy HH, Van Natta ML, Tonascia J, Strunk RC, CAMP Research Group. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367:904-12.
141. Protudjer JL, Lundholm C, Bergström A, Kull I, Almqvist C. The influence of childhood asthma on puberty and height in Swedish adolescents. Pediatr Allergy Immunol. 2015;26:474-81.
142. Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: effects on growth. Evid Based Child Health. 2014;9:829-930.
143. Pruteanu AI, Chauhan BF, Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. Evid Based Child Health. 2014;9:931-1046.
144. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054-63.
145. Loke YK, Blanco P, Thavarajah M, Wilson AM. Impact of inhaled corticosteroids on growth in children with asthma: systematic review and meta-analysis. PLoS One. 2015;10:e0133428.
146. Raissy HH, Blake K. Does Use of inhaled corticosteroid for management of asthma in children make them shorter adults? Pediatr Allergy Immunol Pulmonol. 2013;26:99-101.
147. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: Past lessons and future issues. J Allergy Clin Immunol. 2003;112:S1-40.
148. Sannarangappa V, Jalleh R. Inhaled corticosteroids and secondary adrenal insufficiency. Open Respir Med J. 2014;8:93-100.
149. Lapi F, Kezouh A, Suissa S, Ernst P. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur Respir J. 2013;42:79-86.
150. Issa-El-Khoury K, Kim H, Chan ES, Vander Leek T, Noya F. CSACI position statement: systemic effect of inhaled corticosteroids on adrenal suppression in the management of pediatric asthma. Allergy, Asthma Clin Immunol. 2015;11:9.
151. Todd GR, Wright D, Ryan M. Acute adrenal insufficiency in a patient with asthma after changing from fluticasone propionate to budesonide. J Allergy Clin Immunol. 1999;103:956-7.
152. Dunlop KA, Carson DJ, Shields MD. Hypoglycemia due to adrenal suppression secondary to high-dose nebulized corticosteroid. Pediatr Pulmonol. 2002;34:85-6.
153. Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child. 2002;87(6):457-61.
154. Lovas K, Husebye ES. Addison's disease. Lancet. 2005;365(9476):2058-61.
155. Schwartz RH, Neacsu O, Ascher DP, Alpan O. Moderate dose inhaled corticosteroid-induced symptomatic adrenal suppression: case report and review of the literature. Clin Pediatr (Phila). 2012;51:1184-90.
156. Smith RW, Downey K, Gordon M, Hudak A, Meeder R, Barker S, Smith WG. Prevalence of hypothalamic-pituitary-adrenal axis suppression in children treated for asthma with inhaled corticosteroid. Paediatr Child Health. 2012;17:e34-9.
157. Kamps AW, Molenmaker M, Kemperman R, van der Veen BS, Bocca G, Veeger NJ. Children with asthma have significantly lower long-term cortisol levels in their scalp hair than healthy children. Acta Paediatr. 2014;103:957-61.
158. Smy L, Shaw K, Smith A, Russell E, Van Uum S, Rieder M, Carleton B, Koren G. Hair cortisol as a novel biomarker of HPA suppression by inhaled corticosteroids in children. Pediatr Res. 2015;78:44-7.
159. Deutschbein T, Unger N, Mann K, Petersenn S. Diagnosis of secondary adrenal insufficiency in patients with hypothalamic-pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test. Eur J Endocrinol. 2009;160:9-16.
160. Deutschbein T, Broecker-Preuss M, Flitsch J, Jaeger A, Althoff R, Walz MK, Mann K, Petersenn S. Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. Eur J Endocrinol. 2012;166:613-8.
161. Cornes MP, Ashby HL, Khalid Y, Buch HN, Ford C, Gama R. Salivary cortisol and cortisone responses to tetracosactrin (synacthen). Ann Clin Biochem. 2015;52:606-10.
162. Juniper EF, Stahl E, Doty RL, Simons FER, Allen DB, Howarth PH. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol. 2005;115:S390-413.
163. Chee C, Sellahewa L, Pappachan JM. Inhaled corticosteroids and bone health. Open Respir Med J. 2014;8:85-92.
164. Buehring B, Viswanathan R, Binkley N, Busse W. Glucocorticoid-induced osteoporosis: an update on effects and management. J Allergy Clin Immunol. 2013;132:1019-30.
165. Aljubran SA, Whelan GJ, Glaum MC, Lockey RF. Osteoporosis in the at-risk asthmatic. Allergy. 2014;69:1429-39.
166. Boot AM, de Jongste JC, Verberne AA, Pols HA, de Muinck Keizer-Schrama SM. Bone mineral density and bone metabolism of prepubertal children with asthma after long-term treatment with inhaled corticosteroids. Pediatr Pulmonol. 1997;24:379-84.
167. Allen HD, Thong IG, Clifton-Bligh P, Holmes S, Nery L, Wilson KB. Effects of high-dose inhaled corticosteroids on bone metabolism in prepubertal children with asthma. Pediatr Pulmonol. 2000;29:188-93.
168. Harris M, Hauser S, Nguyen TV, Kelly PJ, Rodda C, Morton J, Freezer N, Strauss BJ, Eisman JA, Walker JL. Bone mineral density in prepubertal asthmatics receiving corticosteroid treatment. J Paediatr Child Health. 2001;37:67-71.
169. van Staa TP, Bishop N, Leufkens HG, Cooper C. Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos Int. 2004;15:785-91.
170. Kelly HW, Van Natta ML, Covar RA, Tonascia J, Green RP, Strunk RC, CAMP Research Group. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics. 2008;122:e53-61.
171. Griffiths AL, Sim D, Strauss B, Rodda C, Armstrong D, Freezer N. Effect of high-dose fluticasone propionate on bone density and metabolism in children with asthma. Pediatr Pulmonol. 2004;37:116-21.
172. Gregson RK, Rao R, Murrills AJ, Taylor PA, Warner JO. Effect of inhaled corticosteroids on bone mineral density in childhood asthma: comparison of fluticasone propionate with beclomethasone dipropionate. Osteoporos Int. 1998;8:418-22.
173. Kaviani N, Bukberg P, Manessis A, Yen V, Young I. Iatrogenic osteoporosis, bilateral HIP osteonecrosis, and secondary adrenal suppression in an HIV-infected man receiving inhaled corticosteroids and ritonavir-boosted highly active antiretroviral therapy. Endocr Pract. 2011;17:74-8.
174. Searing DA, Zhang Y, Murphy JR, Hauk PJ, Goleva E, Leung DYM. Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. J Allergy Clin Immunol. 2010;125:995-1000.
175. Brehm JM, Celedón JC, Soto-Quiros ME, Avila L, Hunninghake GM, Forno E, Laskey D, Sylvia JS, Hollis BW, Weiss ST, Litonjua AA. Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. Am J Respir Crit Care Med. 2009;179:765-71.
176. Fuhlbrigge AL, Kelly HW. Inhaled corticosteroids in children: effects on bone mineral density and growth. Lancet Respir Med. 2014;2:487-96.
177. Lee C, Klaustermeyer WB. Effect of high dose inhaled corticosteroids on cell mediated immunity in patients with asthma. Allergol Immunopathol (Madr). 2012;40:100-3.
178. England RW, Nugent JS, Grathwohl KW, Hagan L, Quinn JM. High dose inhaled fluticasone and delayed hypersensitivity skin testing. Chest. 2003;123:1014-7.
179. Levy J, Zalkinder I, Kuperman O, Skibin A, Apte R, Bearman JE, Mielke Jr PW, Tal A. Effect of prolonged use of inhaled steroids on the cellular immunity of children with asthma. J Allergy Clin Immunol. 1995;95:806-12.
180. Janson C, Larsson K, Lisspers KH, Ställberg B, Stratelis G, Goike H, Jörgensen L, Johansson G. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306.
181. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029-36.
182. Shaikh WA. Pulmonary tuberculosis in patients treated with inhaled beclomethasone. Allergy. 1992;47:327-30.
183. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax. 2013;68:1105-13.
184. Davies JM, Carroll ML, Li H, Poh AM, Kirkegard D, Towers M, Upham JW. Budesonide and formoterol reduce early innate anti-viral immune responses in vitro. PLoS One. 2011;6, e27898.
185. Albano GD, Di Sano C, Bonanno A, Riccobono L, Gagliardo R, Chanez P, Gjomarkaj M, Montalbano AM, Anzalone G, La Grutta S, Ricciardolo FL, Profita M. Th17 immunity in children with allergic asthma and rhinitis: a pharmacological approach. PLoS One. 2013;8, e58892.
186. Wi CI, Kim BS, Mehra S, Yawn BP, Park MA, Juhn YJ. Risk of herpes zoster in children with asthma. Allergy Asthma Proc. 2015;36:372-8.
187. Wu CT, Tsai SC, Lin JJ, Hsia SH. Disseminated varicella infection in a child receiving short-term steroids for asthma. Pediatr Dermatol. 2008;25:484-6.
188. Verstraeten T, Jumaan AO, Mullooly JP, Seward JF, Izurieta HS, DeStefano F, Black SB, Chen RT, Group VSDR. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics. 2003;112:e98-103.
189. Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J. 2014;8:59-65.
190. Egbuonu F, Antonio FA, Edavalath M. Effect of inhaled corticosteroids on glycemic status. Open Respir Med J. 2014;8:101-5.
191. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123:1001-6.
192. Faul JL, Wilson SR, Chu JW, Canfield J, Kuschner WG. The effect of an inhaled corticosteroid on glucose control in type 2 diabetes. Clin Med Res. 2009;7:14-20.
193. Yucel O, Eker Y, Nuhoglu C, Ceran O. Hemoglobin a1c levels in children with asthma using low dose inhaled corticosteroids. Indian Pediatr. 2009;46:300-3.
194. Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Purpura and dermal thinning associated with high-dose inhaled corticosteroids. BMJ. 1990;300:1548-51.
195. Guillot B. Adverse skin reactions to inhaled corticosteroids. Expert Opin Drug Saf. 2002;1:325-9.
196. Monk B, Cunliffe WJ, Layton AM, Rhodes DJ. Acne induced by inhaled corticosteroids. Clin Exp Dermatol. 1993;18:148-50.
197. de Vries TW, de Langen-Wouterse JJ, de Jong-Van den Berg LT, Duiverman EJ. Hypertrichosis as a side effect of inhaled steroids in children. Pediatr Pulmonol. 2007;42:370-3.
198. Bezzina C, Bondon-Guitton E, Montastruc JL. Inhaled corticosteroid-induced hair depigmentation in a child. J Drugs Dermatol. 2013;12:119-20.
199. de Vries TW, De Langden-Wouterse JJ, Van Puijenbroek E, Duiverman EJ, De Jong-Van den Berg LT. Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. Eur J Clin Pharmacol. 2006;62:343-6.
200. Bonala SB, Pina D, Silverman BA, Amara S, Bassett CW, Schneider AT. Asthma severity, psychiatric morbidity, and quality of life: correlation with inhaled corticosteroid dose. J Asthma. 2003;40:691-9.
201. Kumar SS, Nandlal B. Effects of Asthma and Inhalation corticosteroids on the dental arch morphology in children. J Indian Soc Pedod Prev Dent. 2012;30:242-9.
202. Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD. Risk of adverse gastrointestinal events from inhaled corticosteroids. Pharmacotherapy. 2008;28:1325-34.
203. Nowak-Wegrzyn A, Shapiro GG, Beyer K, Bardina L, Sampson HA. Contamination of dry powder inhalers for asthma with milk proteins containing lactose. J Allergy Clin Immunol. 2004;113:558-60.
204. Eda A, Sugai K, Shioya H, Fujitsuka A, Ito S, Iwata T, Funabiki T. Acute allergic reaction due to milk proteins contaminating lactose added to corticosteroid for injection. Allergol Int. 2009;58:137-9.
205. Savvatianos S, Giavi S, Stefanaki E, Siragakis G, Manousakis E, Papadopoulos NG. Cow's milk allergy is a cause of anaphylaxis to systemic corticosteroids. Allergy. 2011;66:983-5.
206. Klok T, Kaptein AA, Duiverman EJ, Brand PL. Long-term adherence to inhaled corticosteroids in children with asthma: Observational study. Respir Med. 2015;109:1114-9.
207. Rust G, Zhang S, McRoy L, Pisu M. Potential savings from increasing adherence to inhaled corticosteroid therapy in Medicaid-enrolled children. Am J Manag Care. 2015;21:173-80.
208. Lee JX, Wojtczak HA, Wachter AM, Lee ML, Burns L, Chen D, Yusin JS. Understanding asthma medical nonadherence in an adult and pediatric population. J Allergy Clin Immunol Pract. 2015;3:436-7.
209. Klok T, Kaptein AA, Brand PL. Non-adherence in children with asthma reviewed: The need for improvement of asthma care and medical education. Pediatr Allergy Immunol. 2015;26:197-205.
210. Mosnaim G, Li H, Martin M, Richardson D, Belice PJ, Avery E, Ryan N, Bender B, Powell L. Factors associated with levels of adherence to inhaled corticosteroids in minority adolescents with asthma. Ann Allergy Asthma Immunol. 2014;112:116-20.
211. Orrell-Valente JK, Jarslberg LG, Hill LG, Cabana MD. At what age do children start taking daily asthma medicines on their own? Pediatrics. 2008;122:e1186-92.
212. Brandt S, Dickinson B. Time and risk preferences and the use of asthma controller medication. Pediatrics. 2013;131:e1204-10.
213. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47:555-67.
214. Van Steenis M, Driesenaar J, Bensing J, Van Hulten R, Souverein P, Van Dijk L, De Smet P, Van Dulmen A. Relationship between medication beliefs, self-reported and refill adherence, and symptoms in patients with asthma using inhaled corticosteroids. Patient Prefer Adherence. 2014;8:83-91.
215. Peláez S, Lamontagne AJ, Collin J, Gauthier A, Grad RM, Blais L, Lavoie KL, Bacon SL, Ernst P, Guay H, McKinney ML, Ducharme FM. Patients' perspective of barriers and facilitators to taking long-term controller medication for asthma: a novel taxonomy. BMC Pulm Med. 2015;15:42.
216. Cooper V, Metcalf L, Versnel J, Upton J, Walker S, Horne R. Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. NPJ Prim Care Respir Med. 2015;25:15026.
217. Capanoglu M, Dibek Misirlioglu E, Toyran M, Civelek E, Kocabas CN. Evaluation of inhaler technique, adherence to therapy and their effect on disease control among children with asthma using metered dose or dry powder inhalers. J Asthma. 2015;52:838-45.
218. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2009;180:817-22.
219. Heaney LG, Horne R. Non-adherence in difficult asthma: time to take it seriously. Thorax. 2012;67:268-70.
220. Krishnan JA, Bender BG, Wamboldt FS, Szefler SJ, Adkinson Jr NF, Zeiger RS, Wise RA, Bilderback AL, Rand CS, Adherence Ancillary Study Group. Adherence to inhaled corticosteroids: an ancillary study of the Childhood Asthma Management Program clinical trial. J Allergy Clin Immunol. 2012;129:112-8.
221. Morton RW, Everard ML, Elphick HE. Adherence in childhood asthma: the elephant in the room. Arch Dis Child. 2014;99:949-53.
222. Chiu KC, Boonsawat W, Cho SH, Cho YJ, Hsu JY, Liam CK, Muttalif AR, Nguyen HD, Nguyen VN, Wang C, Kwon N. Patients' beliefs and behaviors related to treatment adherence in patients with asthma requiring maintenance treatment in Asia. J Asthma. 2014;51:652-9.
223. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-97.
224. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Updated April 2016. Available from: http://ginasthma.org/2016-pocket-guide-for-asthma-management-and-prevention/. Accessed 25 June 2016.
225. Andrade WC, Camargos P, Lasmar L, Bousquet J. A pediatric asthma management program in a low-income setting resulting in reduced use of health service for acute asthma. Allergy. 2010;65:1472-7.
226. Wells KE, Peterson EL, Ahmedani BK, Williams LK. Real-world effects of once s greater daily inhaled corticosteroid dosing on medication adherence. Ann Allergy Asthma Immunol. 2013;111:216-20.
227. Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA. Cost-utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients. J Asthma. 2016;53(5):538-45.
228. Anderson 3rd WC, Szefler SJ. New and future strategies to improve asthma control in children. J Allergy Clin Immunol. 2015;136:848-59.
229. Chan AH, Stewart AW, Harrison J, Camargo Jr CA, Black PN, Mitchell EA. The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial. Lancet Respir Med. 2015;3:210-9.
230. Bender BG, Cvietusa PJ, Goodrich GK, Lowe R, Nuanes HA, Rand C, Shetterly S, Tacinas C, Vollmer WM, Wagner N, Wamboldt FS, Xu S, Magid DJ. Pragmatic trial of health care technologies to improve adherence to pediatric asthma treatment: a randomized clinical trial. JAMA Pediatr. 2015;169:317-23.
231. Mosnaim GS, Pappalardo AA, Resnick SE, Codispoti CD, Bandi S, Nackers L, Malik RN, Vijayaraghavan V, Lynch EB, Powell LH. Behavioral Interventions to Improve Asthma Outcomes for Adolescents: A Systematic Review. J Allergy Clin Immunol Pract. 2016;4:130-41.
232. Mosnaim G, Li H, Martin M, Richardson D, Belice PJ, Avery E, Ryan N, Bender B, Powell L. The impact of peer support and mp3 messaging on adherence to inhaled corticosteroids in minority adolescents with asthma: a randomized, controlled trial. J Allergy Clin Immunol Pract. 2013;1:485-93.
233. Garbutt JM, Sylvia S, Rook S, Schmandt M, Ruby-Ziegler C, Luby J, Strunk RC. Peer training to improve parenting and childhood asthma management skills: a pilot study. Ann Allergy Asthma Immunol. 2015;114:148-9.
234. Gupta D, Behera D, Lalrinmawia H, Dash RJ. Hypothalamo-pituitary-adrenal axis function in asthmatics taking low dose inhaled beclomethasone dipropionate. J Assoc Physicians India. 2000;48:682-4.
235. Drake AJ, Howells RJ, Shield JP, Prendiville A, Ward PS, Crowne EC. Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate. BMJ. 2002;324:1081-2.
236. Todd GR, Acerini CL, Buck JJ, Murphy NP, Ross-Russell R, Warner JT, McCance DR. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Eur Respir J. 2002;19:1207-9.
237. Macdessi JS, Randell TL, Donaghue KC, Ambler GR, van Asperen PP, Mellis CM. Adrenal crises in children treated with high-dose inhaled corticosteroids for asthma. Med J Aust. 2003;178:214-6.
238. Santiago AH, Ratzan S. Acute adrenal crisis in an asthmatic child treated with inhaled fluticasone proprionate. Int J Pediatr Endocrinol. 2010;2010.
239. Zollner EW, Lombard CJ, Galal U, Hough FS, Irusen EM, Weinberg E. Hypothalamic-pituitary-adrenal axis suppression in asthmatic school children. Pediatrics. 2012;130:e1512-9.
240. Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, Jacques L. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J. 2013;7:397-406.
241. Cavkaytar O, Vuralli D, Arik Yilmaz E, Buyuktiryaki B, Soyer O, Sahiner UM, Kandemir N, Sekerel BE. Evidence of hypothalamic-pituitary-adrenal axis suppression during moderate-to-high-dose inhaled corticosteroid use. Eur J Pediatr. 2015;174:1421-31.